Lebrikizumab
DESCRIPTION |
CATALOG # |
SIZE |
PRICE |
Anti-Human IL13 Therapeutic Antibody |
TAB-219 |
1mg |
Please Inquiry |
Product Detail
- Cat
- TAB-219
- Product Overview
- Recombinant monoclonal antibody to IL13. Lebrikizumab (INN) is a humanized monoclonal antibody and an experimental immunosuppresive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids.
- Target
- IL13
- Type
- IgG4 - kappa
- Immunogen
- The details of the immunogen for this antibody are not available.
- Species Reactivity
- Human
- Expression Host
- CHO
- Applications
- Suitable for use in WB, IF, IP, Neut, FuncS, ELISA, FC and most other immunological methods.
- Specificity
- Tested positive against native human antigen.
- Protein Construction
- Immunoglobulin G4-kappa, anti-[Homo sapiens interleukin 13 (IL13,IL-13)], humanized monoclonal antibody
- Predicted N terminal
- H chain: QVTLRES; L chain: DIVMTQS
- Molecular Weight
- 145285
- Purity
- >95%, by SDS-PAGE with silver staining, under reducing conditions.
- Size
- 1mg
- Storage
- Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.
Background
- Antigen Description
- Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
- Function
- cytokine activity; interleukin-13 receptor binding; protein binding;
- Gene ID
- 3596
- Synonyms
- IL13; interleukin 13; interleukin-13; allergic rhinitis; ALRH; BHR1; Bronchial hyperresponsiveness 1 (bronchial asthma); IL 13; MGC116786; MGC116788; MGC116789; P600; Bronchial hyperresponsiveness-1 (bronchial asthma); IL-13;
- Download Datasheet:
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Online Inquiry